ArticleCancer medicine2025
Development and Validation of a Predictive Model for Occult Liver Metastasis in Pancreatic Ductal Adenocarcinoma Using Subjective Imaging and Clinical Data.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is highly lethal, with liver metastases leading to poorer outcomes. Occult liver metastases (OLM), undetected by initial imaging, complicate treatment and diminish survival rates. We aimed to develop and validate a predictive model for occult liver metastasis in pancreatic cancer, which is crucial for effective preoperative planning.
methodsA total of 142 patients with PDAC were retrospectively analyzed between January 1, 2020, and December 31, 2023. Malignant cases were confirmed by pathology, and benign cases were confirmed by pathology or follow-up. Patients were randomly divided into training and validation cohorts at a ratio of 7:3. Factors associated with OLM in PDAC were identified using a stepwise approach, beginning with univariate and followed by multivariate logistic regression analyses. Logistic regression was used to develop clinical, radiological, and combined models, with performance evaluated using the area under the curve (AUC). A nomogram was constructed, and calibration and decision curves were generated. Additionally, machine learning models (RF, SVM, XGBoost) were employed, with AUC and variable importance plots used to evaluate their performance.
resultsTwo clinical and four radiological features independently predicted OLM. The combined model achieved an AUC of 0.86 (training) and 0.84 (validation), outperforming clinical (AUC: 0.73, 0.75) and radiological models (AUC: 0.81, 0.75). Machine learning models showed AUCs of 0.787 (RF), 0.850 (SVM), and 0.851 (XGBoost) in the validation cohort. Decision and calibration curves confirmed the combined model's reliability and clinical utility.
conclusionThe combined model incorporating clinical and radiological features offers a simple, cost-effective tool to identify PDAC patients at high risk for OLMs, supporting informed surgical decisions and improved outcomes. Integrating clinical and radiological markers enhances early detection and personalized care in PDAC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.